Cargando…
Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients
Rituximab is associated with a higher incidence of Pneumocystis jirovecii pneumonia infection. Pneumocystis prophylaxis is advised in many immunocompromised populations treated with rituximab. However, the beneficial effect of pneumocystis prophylaxis in HIV-uninfected, rituximab-treated non-Hodgkin...
Autores principales: | Wei, Kai-Che, Sy, Chenglen, Wu, Shang-Yin, Chuang, Tzu-Jung, Huang, Wei-Chun, Lai, Ping-Chin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5974272/ https://www.ncbi.nlm.nih.gov/pubmed/29844519 http://dx.doi.org/10.1038/s41598-018-26743-4 |
Ejemplares similares
-
Pneumocystis jirovecii pneumonia in non-Hodgkin’s lymphoma after rituximab-based chemotherapy: a case series
por: Zhang, Qianying, et al.
Publicado: (2022) -
Humoral Immune Responses to Pneumocystis jirovecii Antigens in HIV-Infected and Uninfected Young Children with Pneumocystis Pneumonia
por: Djawe, Kpandja, et al.
Publicado: (2013) -
Nomograms for Death from Pneumocystis jirovecii Pneumonia in HIV-Uninfected and HIV-Infected Patients
por: Feng, Qiuyue, et al.
Publicado: (2022) -
P1565: INCIDENCE OF PNEUMOCYSTIS JIROVECII PNEUMONIA IN PATIENTS WITH B-LINEAGE LYMPHOMA RECEIVING CHEMOTHERAPY CONTAINING RITUXIMAB
por: Liang, Xiping Xiping, et al.
Publicado: (2023) -
Pneumocystis jirovecii pneumonia in developing countries
por: De Armas Rodríguez, Y., et al.
Publicado: (2011)